1

2
Wei Sun, Chuncai Song, Xiaoli Chen, Ning Chen, Jun Xiao, Chang Li: Glass suitable for chemical tempering and chemically tempered glass thereof. CDGM Glass, Hamre Schumann Mueller & Larson P C, September 9, 2014: US08828545 (2 worldwide citation)

The invention provides a silica-alumina-sodium oxide glass easy to melt and suitable for a low temperature ion exchange process. The glass is suitable for chemical tempering and consists of 55-60 wt % of SiO2, 0.1-2.5 wt % of B2O3, 11-16 wt % of Al2O3, 14-17 wt % of Na2O, 1-8 wt % of K2O, 0-8 wt % o ...


3
Xiaoli Chen, Keith T Demarest, Jung Lee, Jay M Matthews, Philip Rybczynski: Methods of using substituted tetralins and indanes. Janssen Pharmaceutica, Evelyn D Chen, Jeremy K McKown, April 1, 2008: US07351857 (1 worldwide citation)

The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, diabetes.


4
Matt Chalawsky, Neil C Rhodes, Bin Tian, Alexandr Y Smolyanov, Matthew S Marzilli, Eugen C Nistor, Xiaoli Chen: External-signal influence on content item performance. Google, Leason Ellis, April 22, 2014: US08706550 (1 worldwide citation)

External-signal influence on content item performance is determined. Content item performance data is received that reflects historic performance of a content item for multiple presentations of the content item. Signal data is received that corresponds to at least one signal that is temporally corre ...


5
Jacqueline C Bussolari, Xiaoli Chen, Bruce R Conway, Keith T Demarest, Hamish N M Ross, Rafael Severino: Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators. Ortho McNeil Pharmaceutical, October 2, 2012: US08278268

Combination therapy comprising PPAR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.


6
Jacqueline C Bussolari, Xiaoli Chen, Bruce R Conway, Keith T Demarest, Hamish N M Ross, Rafael Severino: Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators. Ortho McNeil Pharmaceutical, May 22, 2012: US08183213

Combination therapy comprising RXR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.


7
Xiaoli Chen, Keith T Demarest, Jung Lee, Jay M Matthews, Philip Rybczynski: Treating syndrome X with substituted tetralins and indanes. Philip S Johnson, Johnson & Johnson, August 19, 2004: US20040162352-A1

The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, diabetes.


8
Xiaoli Chen, Keith T Demarest, Jung Lee, Jay M Matthews, Philip Rybczynski: Substituted tetralins and indanes. Philip S Johnson, Johnson & Johnson, November 2, 2006: US20060247314-A1

The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, dyslipidemia.


9
Jacqueline C Bussolari, Xiaoli Chen, Bruce R Conway, Keith T Demarest, Hamishi NM Ross, Rafael Severino: Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators. Audley A Ciamporcero Jr, Johnson & Johnson, October 23, 2003: US20030199557-A1

Combination therapy comprising PPAR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.


10